Notice of Meeting and Agenda
Public Board Meeting
September 22, 2016

DATE: September 22, 2016
TIME: 8:00 a.m.
PLACE: Embassy Suites Anaheim Orange
400 N. State College Blvd.
Orange, CA 92868
WEBCAST: http://www.pharmacy.ca.gov/meetings/current_webcasts.shtml
(Webscast will be available earliest at 9:00 a.m. on September 22, 2016. See notices below.)

NOTE: Pharmacists and pharmacy technicians who attend in person may be awarded 6 hours of CE,
in accordance with the Board’s CE policy. Sign in and sign out on the day of the meeting will be
required for the CE credit.

For questions or verification of the meeting, call Laura Hendricks at (916) 574-7918 or access the
board’s Web site at www.pharmacy.ca.gov.

Meeting materials should be available on the board’s Web site at www.pharmacy.ca.gov by
September 19, 2016.

Important Notices to the Public:
The meeting is open to the public and is accessible to the physically disabled. A person who needs a
disability-related accommodation or modification in order to participate in the meeting may make a
request by contacting Laura Hendricks at (916) 574-7918, by emailing laura.hendricks@dca.ca.gov or
sending a written request to the Board of Pharmacy, 1625 N. Market Blvd., Suite N-219, Sacramento, CA
95834. Providing your request at least five business days before the meeting will help to ensure
availability of the requested accommodation.

Discussion and action may be taken on any item on the agenda. The time and order of agenda items are
subject to change at the discretion of the Board President. In accordance with the Bagley-Keene Open
Meeting Act, all meetings of the Board are open to the public. The Board plans to webcast this meeting
on its website at www.pharmacy.ca.gov. Webcast availability cannot, however, be guaranteed due to
limited resources or technical difficulties. The meeting will not be cancelled if webcast is not available. If
you wish to participate or to have a guaranteed opportunity to observe, please plan to attend at a
physical location. Adjournment, if it is the only item that occurs after a closed session, may not be
webcast.

Government Code section 11125.7 provides the opportunity for the public to address each agenda item
during discussion or consideration by the Board or prior to the Board taking any action on said item.
Members of the public will be provided appropriate opportunities to comment on any issues before the
board, but the Board President may, at his or her discretion, apportion available time among those who
wish to speak. Individuals may appear before the Board to discuss items not on the agenda; however,
the Board can neither discuss nor take official action on these items at the time of the same meeting
(Government Code sections 11125, 11125.7(a)).
Agenda

Call to Order 8:00 a.m.

I. Call to Order, Establishment of Quorum, and General Announcements

II. Public Comments on Items Not on the Agenda/Agenda Items for Future Meetings
Note: The board may not discuss or take action on any matter raised during this public comment section that is not included on this agenda, except to decide whether to place the matter on the agenda of a future meeting. [Government Code sections 11125, 11125.7(a)]

III. Petitions for Reinstatement of Licensure or Other Reduction of Penalty
   a. Mumbert, William; RPH 48782
   b. Avalos, Albert; TCH 69538

IV. Closed Session
   a. Pursuant to Government Code Section 11126(c)(3), the Board Will Convene in Closed Session to Deliberate on Disciplinary Matters, Including Petitions for Reinstatement of Licensure or Other Reductions of Penalty, Proposed Decisions, Stipulated Decisions, Defaults, and Any Other Disciplinary Matters.
   b. Pursuant to Government Code section 11126(e), the Board will Convene in Closed Session to Discuss Pending Litigation

V. Reconvene Open Session

VI. Planning Discussion for Future Stakeholders’ Meeting Regarding the Final Rule Implementing Section 1557 of the Affordable Care Act (ACA) Regarding Nondiscrimination in Health Programs and Activities, Specifically Including its Impact on Pharmacy Translations and Interpretations

VII. Discussion and Consideration of Proposed Regulations to Add Title 16 CCR sections 1776 et seq., related to Prescription Drug Take-Back

VIII. Discussion and Consideration of Proposed Regulations to Amend Title 16 CCR section 1732.05, 1732.2 and 1732.5 related to Continuing Education

IX. Pending Compounding Regulations, Title 16 California Code of Regulations, 1735 et seq., and 1751 et seq.; Status Update and Discussion and Consideration of Next Steps, if Necessary

X. Federal Food and Drug Administration’s Draft Guidance Documents – Discussion and Consideration, including Whether to Submit Board Comments, regarding:
   1. Insanitary Conditions at Compounding Facilities
   2. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act
   3. Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act

Adjournment for the Day 5:00 p.m. (or upon conclusion of business)